sacituzumab govitecan
gilead sciences
['tropics-02', 'sacituzumab govitecan']
 presents exciting news on primary results from tropics-02: a randomized phase 3 study of sacituzumab govitecan versus treatment of physician s choice in patients with hormone receptor positive/her2-negative advanced. hall d1 at 1:27 pm. #asco22 
Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements